Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

TAE-684

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis, Scripps Research Institute

Drug class:

ALK inhibitor, LRRK2 inhibitor

Related drugs:

ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D
NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D
NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D
Chr t(2;17)(p23;q23) CLTC/ALK	Diffuse Large B Cell Lymphoma	Chr t(2;17)(p23;q23) CLTC/ALK	Diffuse Large B Cell Lymphoma	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D
NPM1-ALK I1171N	Non-Hodgkin’s Lymphoma	NPM1-ALK I1171N	Non-Hodgkin’s Lymphoma	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D
NPM1-ALK L1196Q	Non-Hodgkin’s Lymphoma	NPM1-ALK L1196Q	Non-Hodgkin’s Lymphoma	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D
ALK F856S	Leukemia	ALK F856S	Leukemia	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D
ALK A348D	Leukemia	ALK A348D	Leukemia	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D